Boardroom Media (CEO News)
At CEO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based CEO’ operating in the Biopharma space. If you think a CEO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Jonathan Montagu
President & Chief Executive Officer of HotSpot Therapeutics
Follow Jonathan Montagu:
About Atlas Venture, HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Pieter Muntendam
President and CEO of SQ Innovation
Follow Pieter Muntendam:
About G3 Pharmaceuticals, SQ Innovation: SQ Innovation is a biopharmaceutical company that develops and commercializes pharmaceutical products.
George Scangos
CEO of Vir Biotechnology
George A. Scangos, Ph.D., is the chief executive officer and a member of the Board of Directors of VIR. Previously, he was the chief executive officer and a member of the board of directors of Biogen since July 2010. From 1996 to July 2010, Dr. Scangos served as the president and chief executive officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University, where he is still an adjunct professor. Dr. Scangos served as non-executive chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He currently serves on the Boards of Directors of Agilent, Exelixis, and Decibel Therapeutics.
Follow George Scangos:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Brian Stuglik
CEO of Verastem Oncology
Brian Stuglik was appointed to Chief Executive Officer (CEO) of Verastem Oncology in July, 2019. Mr. Stuglik is a global leader in the oncology pharmaceutical sector with over 3 decades of experience in US and International pharmaceutical development, product strategy, commercialization and business development. He successfully developed, acquired and launched several multi-billion dollar oncology brands across multiple tumor types and therapeutic approaches. Brian founded Proventus Health Solutions, a company specializing in helping oncology biotech companies create greater value by integrating development and commercial considerations into a unified approach. Currently, he serves as a member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO).
Follow Brian Stuglik:
About Verastem Oncology: Verastem is a biopharmaceutical company that focuses on discovering and developing novel drugs that selectively target cancer stem cells.
Liang Schweizer
Co-founder, President and CEO of HiFiBiO
Liang Schweizer is the Co-founder, President and CEO of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates. Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.
Follow Liang Schweizer:
About HiFiBiO: HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.
Jon Heimer
CEO of Olink
As President and CEO of Olink Proteomics the vision and goal is to facilitate and implement Precision Medicine via discovery and development of validated protein targets to identify smaller protein signatures for e.g. stratification and prediction and advance them in to clinical decision making. Jon is an entrepreneur and has spent the last 25 years in various biotech start-up companies, developing and commercializing medical devices and biotech drugs. He studied economy at the Uppsala University and has an MBA from IHM Business school in Stockholm. Jon was part of a small team that started Swedens latest most successful biotech which grew to 800 people around the world, market leader in its segment, went public and eventually sold to Galderma. Prior to joining Olink Proteomics as President and CEO he ran a small orphan drug company developing two drugs into late stage clinical trials through the FDA with novel treatments for hyperoxaluria.
Follow Jon Heimer:
About Olink: Olink develops ground-breaking technologies for biomolecular analysis.
Chen Schor
Co-Founder, President & CEO of resTORbio
Schor is a global healthcare industry leader with vast experience in pharmaceuticals, biotechnology, medical devices, business development and private equity. Schor has supported and helped build multiple healthcare companies and led multiple licensing, partnerships and M&A transactions with total value exceeding $8 billion with companies such as GSK, Amgen, Pfizer, Bayer, Teva and EMD-Serono. Prior to joining Novalere, Schor was VP Global Business Development with Teva Pharmaceuticals and had leadership roles at several emerging pharmaceutical and biotechnology companies. Schor was also a Partner at Yozma venture capital where he led the foundation and growth of multiple companies from inception to significant commercial success. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics, and is also a Certified Public Accountant (CPA).
Follow Chen Schor:
About Novalere FP, Predix Pharmaceuticals, resTORbio, Synta Pharmaceuticals: resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.
Richard Labaudinière
CEO of Protego Biopharma
Richard Labaudiniere currently works as the Chief Executive Officer for Protego Biopharma.
Follow Richard Labaudinière:
About Protego Biopharma: Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy.
Michael Gilman
CEO of Arrakis Therapeutics
Michael Gilman, Ph.D. has served as a member of our board of directors since November 2013. Michael Gilman is currently Chairman and Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016, and Chief Executive Officer and Director for Obsidian Therapeutics, Inc., a role he has served in since 2016. Previously, from 2014 to 2016 Michael Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Michael Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Michael Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Michael Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Michael Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of X4 Pharmaceuticals, Inc. and the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. Michael Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology.
Follow Michael Gilman:
About Arrakis Therapeutics, Obsidian Therapeutics: Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Michael Gilman
Chief Executive Officer of Arrakis Therapeutics
Follow Michael Gilman:
About Arrakis Therapeutics: Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Ajikumar Parayil
CEO & Founder of Manus Bio
Follow Ajikumar Parayil:
About Manus Bio, Mirakel Technologies: Manus Bio makes nature accessible and affordable for a growing society.
Tim Guilliams
Founder, CEO of Healx
Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).
Follow Tim Guilliams:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
David R. Elmaleh
Scientific Founder, CEO and Chairman of AZTherapies
David R. Elmaleh is the founder of [Mersana Therapeutics](https://www.crunchbase.com/organization/mersana-therapeutics#/entity). Previously, he served as the chairman and president of AZTherapies. Elmaleh obtained a bachelor’s degree in chemistry and physics, and master’s degree and PhD in organic chemistry from Hebrew University.
Follow David R. Elmaleh:
About AZTherapies, Mersana Therapeutics: AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Laura E. Benjamin
CEO & President of OncXerna Therapeutics
Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies.
Follow Laura E. Benjamin:
About OncXerna Therapeutics: OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
Heather Fairhead
Founder & CEO of Phico Therapeutics
Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.
Follow Heather Fairhead:
About Phico Therapeutics: Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Juergen Horn
Founder and CEO of Invetx
Juergen Horn is the founder and CEO of Invetx.
Follow Juergen Horn:
About Invetx: Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.
Tina Liu
Founder, CEO of Ally Therapeutics
Tina Liu is the Founder and CEO at Ally Therapeutics.
Follow Tina Liu:
About Ally Therapeutics: Ally Therapeutics solves the immune response barriers for gene therapy.
Ruiping Dong
CEO of Haihe Biopharma
Chairman and CEO of Shanghai RMX BioPharma. Former Senior VP & President of R&D for Emerging Markets of MSD, Global VP & President of R&D for Japan/China of BMS, and Medical Director of oncology clinical research of Astra Zeneca. National “1000 Talents” Expert. MD of Kyushu U. Medical School, Japan. Post-Doc at Dana-Farber Cancer Institute, Harvard Medical School.
Follow Ruiping Dong:
About Haihe Biopharma: Haihe Biopharma is a biopharmaceutical company that develops cancer anti-tumour drugs.
John Glasspool
CEO & President of Anthos Therapeutics
John Glasspool is the chief executive officer at Anthos Therapeutics.
Follow John Glasspool:
About Anthos Therapeutics: Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.
Frank Borriello
Founder and CEO of Alloplex Biotherapeutics
Frank Borriello is the Founder and CEO at Alloplex Biotherapeutic.
Follow Frank Borriello:
About Alloplex Biotherapeutics: Alloplex Biotherapeutics is a privately held Boston based cellular therapeutics company.
